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1<Abstract>
Early Treatment Volume Reduction Rate as a Prognostic Factor in 
Patients Treated with Chemoradiotherapy for Limited Stage Small Cell 
Lung Cancer
Joohwan Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Chang Geol Lee)
Purpose: To investigate the relationship between early treatment response to 
definitive chemoradiotherapy (CRT) and survival outcome in patients with limited 
stage small cell lung cancer (LS-SCLC)
Materials and Methods: We retrospectively reviewed 47 patients with LS-SCLC who 
received definitive CRT between January 2009 and December 2012. Patients were 
treated with systemic chemotherapy regimen of etoposide/carboplatin (n = 15) or 
2etoposide/cisplatin (n = 32) and concurrent thoracic radiotherapy at a median dose of 
54 Gy (range, 46-64 Gy). Early treatment volume reduction rate (ETVRR) was 
defined as the percentage change in gross tumor volume between diagnostic 
computed tomography (CT) and simulation CT for adaptive RT planning and was 
used as a parameter for early treatment response. The median dose at adaptive RT 
planning was 36 Gy (range, 30-43 Gy), and adaptive CT was performed in 30 patients 
(63.8%).
Results: With a median follow-up of 27.7 months (range, 5.9-75.8 months), the two-
year loco-regional progression-free survival (LRPFS) and overall survival (OS) rates 
were 74.2% and 56.5%, respectively. The mean diagnostic and adaptive gross tumor 
volumes were 117.9 cc (range, 5.9-447 cc) and 36.8 cc (range, 0.3-230.6 cc), 
respectively. The median ETVRR was 71.4% (range, 30-97.6%) and the ETVRR >45% 
group showed significantly better OS (p <0.0001) and LRPFS (p = 0.009) than the 
other group.
Conclusions: ETVRR as a parameter for early treatment response may be a useful 
prognostic factor to predict treatment outcome in LS-SCLC patients treated with CRT.
Key words: small cell lung carcinoma, gross tumor volume, early treatment 
response, volume reduction rate
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I. INTRODUCTION
Small cell lung cancer (SCLC) is a well-known subtype of lung cancer that 
is diagnosed almost exclusively in patients with a smoking history.1 SCLC comprised 
13% of new lung cancer diagnoses in 2011, and limited stage (LS)-SCLC accounts for 
approximately 30% to 40% of these cases in the USA.2 The current standard treatment 
for SCLC is systemic chemotherapy with concurrent thoracic radiotherapy (RT) for 
consolidation. While this cancer shows favorable response to treatment, it still has
poor survival outcome.3,4
4Prognostic factors for survival in SCLC include stage, age, sex, the World 
Health Organization performance score (WHO-PS), serum lactate dehydrogenase 
(LDH) level, N3 nodal status, and time from the start of any treatment to the end of 
radiation therapy (SER).5 The T stage is a significant prognostic factor for lung cancer, 
but it contains only bi-dimensional measurements of gross tumor. The International 
Commission on Radiation Units & Measurements (ICRU) 50 report6 defines gross 
tumor volume (GTV) as the gross palpable or visible/demonstrable extent and 
location of malignant growth and is the basic concept of three-dimensional conformal 
radiation therapy (3DCRT). Initial GTV is a prognostic factor for non-small cell lung 
cancer (NSCLC) patients treated with chemoradiotherapy (CRT)7 and has been 
studied as an independent prognostic factor for survival in SCLC.8
The volume reduction rate (VRR) during RT is a possible indicator of 
biological tumor radiosensitivity and serves as a clinical marker of treatment outcome. 
In advanced rectal cancer patients treated with neoadjuvant CRT, Kim et al.9 revealed 
a difference in tumor VRR between patients who were down-staged by neoadjuvant 
treatment and those who were not. Among head and neck (oropharyngeal or 
hypopharyngeal) cancer patients treated with definitive CRT using intensity-
modulated RT (IMRT), VRR was a significant indicator of local control rate.10
Werner-Wasik et al.11 investigated the volumetric response of 22 locally-advanced 
NSCLC patients treated with non-surgical therapy including thoracic RT. VRR was 
one of the most effective tools for evaluating treatment response.
5However, no studies investigate the prognostic effect of tumor volume 
change between initial presentation and adaptive RT planning on SCLC survival 
outcome. The aim of the current study is to investigate the relationship between 
treatment response and outcome in patients with LS-SCLC.
6II. MATERIALS AND METHODS
1. Patients
We retrospectively reviewed the medical records of 106 patients with SCLC 
who underwent CRT with definitive aim between January 2009 and December 2012. 
A diagnosis of SCLC was confirmed histologically in all patients. SCLC is staged by 
the Veterans Administration Lung Study Group (VALSG) staging system,12 according 
to which patients are classified as having limited disease (LD) or extensive disease 
(ED). Patients with LD have tumor confined to the ipsilateral hemithorax, without any 
malignant effusion, with disease that may be incorporated in a single radiation beam 
field. Disease that does not fulfill these criteria is defined as ED. Limited/extensive 
staging was determined based on imaging studies, including both diagnostic CT and 
positron emission tomography (PET)-CT. All eligible patients were also staged 
according to the 7th American Joint Committee on Cancer (AJCC) TNM staging 
system.13
Exclusion criteria included extensive-stage disease (n = 19), more than one 
primary cancer that could affect survival outcome (n = 6), loss of follow-up after 
completion of treatment (n = 4), incomplete RT less than 45 Gy (n = 3), incomplete 
chemotherapy less than four cycles (n = 13), and chemotherapy regimen other than 
etoposide/cisplatin (EP) or etoposide/carboplatin (EC) (n = 14). Finally, 47 patients 
were enrolled in the study.
72. Pretreatment evaluation and follow-up
Pretreatment evaluation included 1) complete history and physical 
examination, 2) biopsy for histological diagnosis, 3) laboratory studies, including 
complete blood cell counts and hepatic/renal functions, and 4) imaging studies for 
staging such as chest X-ray, chest CT, brain magnetic resonance imaging (MRI), and 
PET-CT. Patients were followed with chest CT and/or PET-CT one month after 
radiotherapy, every three months within the first year, every six months in the second 
year, and once a year thereafter. Treatment response was evaluated with follow-up CT 
performed one and three months after RT using the Response Evaluation Criteria in 
Solid Tumors (RECIST) guidelines, version 1.1.14
3. Treatment
A. Chemotherapy
To evaluate changes of tumor volume in response to RT evenly, we limited 
the concurrent chemotherapy regimen to only EP (n = 15) or EC (n = 32). The 
treatment schedule was consisted of cisplatin or carboplatin on day 1 with etoposide 
on days 1 to 3 for four to six cycles (average 4.3 cycles), and repeated every three
weeks. The standard chemotherapy dose was 120mg/m2 etoposide with 60mg/m2
cisplatin for the EP regimen and 100mg/m2 etoposide for the EC regimen. Carboplatin 
in the EC regimen dose was calculated based on the target area under the curve (AUC) 
as (5 mg/ml/h x (glomerular filtration rate [GFR] + 25)). GFR was calculated with the 
8Cockroft-Gault formula.15 During treatment, six patients required a dose reduction 
due to hematologic toxicities more severe than RTOG grade 1. There was a difference 
in volume between diagnostic CT and planning CT because RT started with the 
second cycle of chemotherapy in most patients (n = 35).
B. Radiotherapy
All patients were treated with 3DCRT. Planning CT was performed with 
contrast and a 3-mm thickness for each scan slice. For respiration-dependent organ 
motion, fluoroscopy (Simulix EvolutionTM, Nucletron, Veenendal, Netherlands) was 
used in 18 patients prior to July 2010, and a four-dimensional CT system (Anzai 
Medical, Tokyo, Japan) that acquired images in 12 phases was used in 29 patients 
afterward that date.
For patients undergoing 2D fluoroscopy, GTV was defined as primary tumor 
and involved regional lymph nodes (LN) identified in the planning chest CT. The 
PET-CT was fused with the planning CT for target delineation in all but one patient 
(97.9%). Clinical target volume (CTV) was defined as GTV plus a 10 to 15 mm 
margin in order to include microscopic tumor extension. Planning target volume 
(PTV), for adapting errors which could occur through set-up variation and respiratory
motion, was defined as CTV plus an additional 5 to 15 mm margin, depending on 2D 
fluoroscopy results. For patients undergoing 4DCT, GTV was contoured on the mid-
ventilation, maximum inhalation and exhalation phases in order to reflect respiration. 
9CTV was defined as GTV plus a 10 to 15 mm margin expansion, and PTV was 
defined as an additional 5 mm margin beyond the CTV.
One patient was treated with IMRT, and 46 patients were treated with 
3DCRT. Three to five coplanar isocentric fields were designed for the initial 3DCRT 
plan, which used PinnacleTM radiotherapy treatment planning (RTP) systems (Philips 
Radiation Oncology Systems, Milpitas, CA, USA) or MIMTM software version 6.3.7 
(MIM Software, Cleveland, OH, USA). An additional simulation CT was performed 
to evaluate GTV shrinkage during RT, and adaptive planning focused on accurate 
tumor targeting and preservation of adjacent normal organs (i.e., normal lung volume, 
esophagus). For this adaptive planning, we used a larger number of coplanar 
isocentric beams. In the patient treated with IMRT, the RT plan was designed to 
deliver 56 Gy to 95% of the PTV using six coplanar MV beams through a helical 
tomotherapy planning system. Definitive CRT was followed by prophylactic cranial 
irradiation (PCI) in patients showing complete or partial response.
4. Volumetric parameters
For each patient, we contoured GTVs in four sets of CT images: diagnostic,
planning, adaptive, and follow-up CT images. ‘Diagnostic CT’ was defined as the first 
chest CT that contains a malignant lung mass confirmed by a chest radiologist. Chest 
CTs performed at other hospitals were also registered in our PACS (Picture Archiving 
and Communication System) (GE Healthcare, Milwaukee, WI, USA) and fused with 
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the ‘planning CT’ for target contouring. ‘Adaptive CT’ was defined as a chest 
simulation CT performed at the time of adaptive RT planning, using the same setting 
as the planning CT. ‘Follow-up CT’ was conducted for evaluation of the best 
treatment response between one and three months after completion of RT.
When contouring each GTV, we used MIM software version 6.3.7 and 
homogenized window settings for CT density in order to reduce errors. We defined a 
lung setting with a window of 1324 and a level of -362 for contouring GTV localized 
at the lung parenchyme and a mediastinum setting with a window of 500 and a level 
of 39 for regional LNs.
We proposed overall volume reduction rate (OVRR) as a parameter for 
overall treatment response that appeared as percentage change in GTV between 
diagnostic CT and follow-up CT. To evaluate early treatment response, we calculated 
early treatment volume reduction rate (ETVRR) as an indication of the percentage 
change in GTV obtained when comparing diagnostic CT with adaptive CT. 
Additionally, we measured early chemotherapy volume reduction rate (ECVRR) for 
pure evaluation of first cycle chemotherapy response defined as the percentage 
change in GTV between diagnostic CT and planning CT.
5. Statistical analysis
LRPFS, distant metastasis-free survival (DMFS), PFS, and OS were 
calculated from the date of diagnosis to the event and were plotted using the Kaplan-
Meier method. We dichotomized patients upon VRR with every 5% interval around 
11
median to find out most effective cut-off value. For analyzing the relationship 
between the time interval from first chemotherapy to first RT and ETVRR, we used 
the Kruskal-Wallis test. 
Univariate survival analyses for several prognostic factors were also
processed with the Kaplan-Meier method. To create multivariate model, we used 
stepwise logistic regression with variables entry at p <0.15 and removed if the p value 
was ≥0.15. Patient survival status was confirmed in February 2013. In our study, all 
statistical analyses were performed using SPSS version 20.0.0 (SPSS Inc., Chicago, 
IL, USA). A p-value < 0.05 was considered statistically significant.
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III. RESULTS
1. Patient characteristics 
The median patient age was 68 (range, 40 to 84), and 42 patients (89.4 %) 
were male. At the time of diagnosis, 41 patients (87.2%) had the Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0 (n = 12) to 1 (n = 29).
According to the AJCC 7th TNM staging system,13 five patients were Stage I (10.6%), 
four patients were Stage II (8.5%) and 38 patients were Stage III (80.9%). The median 
thoracic RT dose was 54 Gy (range, 46 to 64 Gy), with a median daily dose of 2 Gy 
(range, 1.8 to 2.5 Gy). The median time interval between diagnostic and planning CT
was 32 days (range, 9 to 123 days). The date of first chemotherapy was a median of 
22 days (range, 0 to 161 days) earlier than the date of first RT. Most patients started 
RT concurrently with 1st (n = 8) or 2nd (n = 35) cycle chemotherapy and other four 
patients received delayed RT because of poor general condition status (n = 2) or 
neutropenia caused by initial chemotherapy (n = 2).
Adaptive CT was conducted at a median RT dose of 36 Gy (range, 28.8 to 43 
Gy) and was performed in 30 patients (63.9%). After completion of CRT, 38 patients 
(80.9%) underwent prophylactic cranial irradiation (PCI). Patient characteristics are 
provided in Table 1.
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Table 1. Patient and treatment characteristics
Variables
No. of 
Patients
(%)
Age, years
  Median 68
  Range 40-84
Sex
  Male 42 (89.4)
  Female 5 (10.6)
ECOG Performance status
  0 12 (25.5)
  1 29 (61.7)
  2 6 (12.8)
T Stage
  1-2 22 (46.8)
  3-4 25 (53.2)
N Stage
  0-2 32 (68.1)
  3 15 (31.9)
AJCC Stage
  IA 3 (6.4)
  IB 2 (4.3)
  IIA 3 (6.4)
  IIB 1 (2.1)
  IIIA 15 (31.9)
  IIIB 23 (48.9)
Chemotherapy
  Regimen
    Etoposide/carboplatin 15 (31.9)
    Etoposide/cisplatin 32 (68.1)
  Cycle
    4 39 (83.0)
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Variables
No. of 
Patients
(%)
    5 1 (2.1)
    6 7 (14.9)
Radiotherapy
  Modality
    3DCRT  46 (97.9)
    Tomotherapy 1 (2.1)
  Dose, Gy
    Median 54
    Range 46-64
Prophylactic cranial irradiation
  Yes 38 (80.9)
  No 9 (19.1)
SER, days
  Median 64
  Range 36-203
Abbreviations: ECOG = Eastern Cooperative Oncology Group; AJCC = American 
Joint Committee on Cancer; 3DCRT = three-dimensional conformal radiation therapy; 
SER = start of any treatment to the end of radiation therapy.
2. Treatment response and pattern of failure
Five patients (10.6%) achieved a complete response (CR), 40 patients 
achieved a partial response (PR) (85.1%), and two patients had stable disease (SD) 
(4.3%). With a median follow-up time of 27.4 months (range, 6.2 to 66.4 months), the 
two-year LRPFS and DMFS rates were 74.2% and 70.1%, respectively. Two-year 
PFS and OS rates were 50.6% and 56.5%, respectively (Figure 1). Of the total 
patients, 17 (36.2%) experienced loco-regional failure, 17 (36.2%) had distant failure, 
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and seven (14.9%) had both. Sites of distant failure included brain (n = 9), bone (n = 
2), adrenal gland (n = 2), liver (n = 2), and intra-abdominal LNs including the para-
aortic area (n = 1). One patient had multifocal sites, including the brain, left seventh 
rib, and LN around the celiac trunk.
Figure 1. Kaplan-Meier survival curves (A) Overall survival, (B) Progression-
free survival, (C) Loco-regional progression-free survival, and (D) Distant 
metastasis-free survival
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3. Volumetric parameters related to survival outcomes
The volumetric parameters measured in this study are described in Table 2. 
The mean GTV of diagnostic, planning, adaptive, and follow-up CT were 117.9 cc 
(range, 5.9 to 447 cc), 68.7 cc (range, 2.5 to 391 cc), 36.8 cc (range, 0.3 to 230.6 cc), 
and 20.6 cc (range, 0.1 to 102.1 cc), respectively. Every patient experienced volume 
reduction in each CT when treated with CRT. The median OVRR was 81.6% (range, 
44.2 to 99%), median ECVRR was 53.5% (range, 0 to 82.3%) and the median 
ETVRR of 30 patients with adaptive CT was 71.4% (range, 30 to 97.6%).
ETVRR was a statistically effective prognostic factor for OS (p = 0.012) and 
PFS (p = 0.015). In the univariate analysis with median cut-off value, initial GTV, 
OVRR, ECVRR, and ETVRR showed no prognostic impact on survival outcome (all 
p >0.05). To reveal most effective cut-off value of VRR, we assessed every 5% 
interval around median. By this process, we concluded that ETVRR with 45% cut-off 
value correlated significantly with OS (p <0.0001) and LRPFS (p = 0.009) (Table 3).
The median OS and LRPFS were 31.3 and 47.5 months for patients with greater than 
45% ETVRR, respectively, compared with 8.3 and 6.3 months for those with a lower 
than 45% value (Figure 2). Nodal status was a statistically significant prognostic 
factor of DMFS when comparing the N3 group versus N0-2 group (p = 0.049). Other 
factors of age, sex, ECOG PS, stage except for nodal status, RT dose, SER, PCI did 
not show statistically significant difference with regard to survival outcomes.
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Table 2. Volumetric parameters (Gross tumor volume and volume reduction rate)
Image Gross tumor volume (cc)
Diagnostic CT (n = 47)
    Mean 117.9
    Range 5.9-447
Planning CT (n = 47)
    Mean 68.7
    Range 2.5-391
Adaptive CT (n = 30)
    Mean 36.8
    Range 0.3-230.6
Follow-up CT (n = 47)
    Mean 20.6
    Range 0.1-102.1
Response Volume reduction rate (%)
Overall
    Median 81.6 (± 13.5)
    Range 44.2-99
Early Chemotherapy
    Median 53.5 (± 25.9)
    Range 0-82.3
Early Treatment
    Median 71.4 (± 16.6)
    Range 30-97.6
Abbreviations: CT = computed tomography
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Figure 2. Results based on early treatment volume reduction rate (A) Overall 
survival and (B) Loco-regional progression-free survival
19
Table 3. Univariate analysis of prognostic factors
Variable n
2yr OS 
(%)
p
2yr PFS
(%)
p
2yr LRPFS
(%)
p
2yr DMFS
(%)
p
Age ≤70 29 46.5 0.274 30.4 0.232 64.7 0.048 69.3 0.279
>70 18 72.2 44 88.1 70.5
Sex Male 42 57.1 0.484 50.1 0.911 73.6 0.748 70.1 0.725
Female 5 50 53.3 80 66.7
ECOG PS <2 41 60 0.083 52.8 0.669 76.4 0.72 69.6 0.786
≥2 6 33.3 25 50 66.7
T Stage 1-2 22 57.3 0.483 55.2 0.999 70.6 0.311 76.7 0.389
3-4 25 56 46.7 77.8 64.3
N Stage 0-2 32 64.6 0.203 55.5 0.548 73.4 0.625 77.8 0.049
3 15 40 39.1 73.3 53.9
Stage I-IIIA 24 65.3 0.539 57.6 0.732 72.4 0.479 84.2 0.135
IIIB 23 47.8 43.7 75.8 56.3
RT dose, Gy ≤54 32 61.3 0.195 47.4 0.825 73.4 0.82 65 0.968
>54 15 46.7 61.8 76.6 84
SER, days ≤64 24 56.5 0.754 54 0.614 72.2 0.58 71.8 0.846
>64 23 56.5 46.6 71 68.8
PCI Yes 38 54.1 0.317 52.8 0.22 75.7 0.446 74.4 0.168
No 9 66.7 40 85.7 53.3
Initial GTV, cc ≤90 24 61 0.73 46.6 0.225 74 0.686 62.3 0.077
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Variable n
2yr OS 
(%)
p
2yr PFS
(%)
p
2yr LRPFS
(%)
p
2yr DMFS
(%)
p
>90 23 52.2 54.9 74.2 77.6
OVRR, % ≤80 20 50 0.667 38.8 0.439 62.2 0.564 64.9 0.87
>80 27 61.5 59.1 82.7 74.2
ECVRR, % ≤50 25 44 0.161 38.2 0.551 67.3 0.842 60.6 0.243
>50 22 71.4 62.2 81.3 79.4
ETVRR, % ≤45 3 0 <0.0001 0 0.138 0 0.009 0 0.556
>45 27 61.5 44.7 70.3 73.9
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance score; RT = radiotherapy; SER = start of any 
treatment to the end of radiation therapy; PCI = prophylactic cranial irradiation; GTV = gross tumor volume, OVRR = overall 
volume reduction rate; ECVRR = early chemotherapy volume reduction rate; ETVRR = early treatment volume reduction rate; 
yr = year; OS = overall survival; PFS = progression-free survival; LRPFS = loco-regional progression-free survival; DMFS = 
distant metastasis-free survival
21
Because ETVRR was the only significant prognostic factor in the univariate 
analysis, we assessed the backward stepwise multivariate analysis and ETVRR was 
also shown as the only statistically significant factor for OS (HR, 0.117; 95% CI, 
0.026-0.530, p = 0.005) and LRPFS (HR, 0.064; 95% CI, 0.007-0.601, p = 0.016) 
(Table 4).  
We additionally analyzed the relationship between the time interval from 
first chemotherapy to first RT and ETVRR. Patients were divided into three groups 
depend on the timing of RT start. Group 1 (n = 8) and group 2 (n = 35) started RT 
with 1st and 2nd cycle of chemotherapy, and group 3 (n = 4) started RT with 3rd or 
thereafter. Median ETVRR of each group was 70.5%, 76.9%, and 66.7%, respectively, 
and there was no statistical difference between the time interval and ETVRR (p = 
0.619). 
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Table 4. Multivariate logistical regression analyses of prognostic factors
Variable
OS LRPFS
HR 95% CI p HR 95% CI p
Age, >70yr vs. ≤70yr 0.226 0.048-1.072 0.061
Sex, Male vs. Female 0.27 0.034-2.126 0.214 6.009 0.502 71.951
N Stage, 0-2 vs. 3 0.207 0.023-1.86 0.16
ETVRR, >45% vs. ≤45% 0.117 0.026-0.530 0.005 0.064 0.007-0.601 0.016
Abbreviations: yr = year; OS = overall survival; LRPFS = loco-regional progression-
free survival; HR = hazard ratio; CI = confidence interval; ETVRR = early treatment 
volume reduction rate
23
IV. DISCUSSION
This aim of this study was to determine prognostic factors influencing CRT 
outcome for LS-SCLC, including tumor volume parameters such as OVRR, ECVRR
and ETVRR. We hypothesized that initial GTV and VRR of gross tumor are 
prognostic factors related to patient survival. The median OVRR was 81.6%, showing 
substantial GTV reduction within three months after RT; however, an OVRR >80% 
was not a statistically significant prognostic factor of any survival outcome. The 
median ETVRR was 71.4% (range, 30 to 97.6%), which showed a substantial degree 
of GTV reduction during early CRT, reflecting the radiosensitivity of SCLC. An 
ETVRR >45% was a significant prognostic factor of OS (p <0.0001) and LRPFS (p = 
0.009).
Tumor volume defined in CT images is a main concept of 3DCRT. Before 
the CT era, the largest longitudinal diameter was the only detectable prognostic factor 
related to tumor size. In RTOG 73-01,16 tumor diameter measurement was based on 
posterior-anterior and lateral chest radiography. With this two-dimensional assessment, 
91% of patients treated with 60 Gy showed CR, PR or SD status and only 9% had a 
progressive response. Such favorable outcomes differ considerably from the outcomes 
of more recent studies of lung cancer treatment. To compensate for this over-
estimation, the definition of CR was changed to include radiographic, clinical, and 
bronchoscopic results.17,18 However, these methods are still less objective than image-
only method due to inter-observer variation. The AJCC TNM staging system,13 one of 
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most widely accepted prognostic factors of lung cancer, also uses greatest tumor 
dimension based on CT images for T staging. 
After the introduction of 3DCRT for cancer treatment, physicians began to 
contour the tumor shape on each planning CT slice. Tumor volume was considered as 
a possible prognostic factor based on clinical experiences. Volumetric tumor 
measurement was also considered more objective and accurate than clinical 
evaluation of tumor response. 
There have been several studies regarding initial tumor volume as a 
prognostic factor in lung cancer. Bradley et al.19 demonstrated that GTV was a
prognostic factor for OS and cause-specific survival in NSCLC treated with 3DCRT 
planning. In that study, T, N, and overall stage were not statistically significant 
prognostic factors. Werner-Wasik et al.20 investigated the efficacy of initial GTV for 
NSCLC patients in the RTOG 93-11 phase I-II trial. In their dose-escalation study, 
patients with tumor volume smaller that 45cm3 achieved better median survival time 
and PFS compared to those of patients with larger tumors. Basaki et al.21 also showed 
that primary tumor volume had an impact on OS in 71 NSCLC stage III patients 
treated with definitive CRT (n = 45) or RT alone (n = 26). In that study, gross tumor 
volume and total tumor volume were statistically meaningful, but nodal volume alone 
was not. Koo et al.22 conducted a single-institution study that retrospectively reviewed
191 patients with stage III NSCLC who underwent CRT. They concluded that smaller 
pre-treatment GTV is an independent prognostic factor of better OS, PFS, and LRPFS 
(all p < 0.05). They also studied the impact of VRR as a prognostic factor of survival 
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outcome; however, it showed only a trend of OS (p = 0.075). Reymen et al.8 revealed 
total GTV, including gross tumor with selective LNs to be irradiated, as an 
independent prognostic factor of overall survival in stage I to III SCLC. This was the 
first study to show the prognostic significance of total GTV in SCLC. Initial GTV 
was not a prognostic factor in this study, and OVRR was also not statistically 
significant. We hypothesize that these results are due to the small number of patients 
and the fact that SCLC has a favorable treatment response, as reported in previous 
studies,23 so almost every patient experienced substantial volume reduction at follow-
up CT.
A limited number of studies have concentrated on the rate of 3D volume 
reduction. VRR was studied in head and neck cancer by Yang et al.10 and was an 
effective predictor of local control in oropharynx and hypopharynx cancer patients 
treated with IMRT. Therefore, it was recommended that patients who showed a less 
than 50% volume reduction should be considered for other treatment options like 
salvage surgery or escalated dose prescription. In 2001, Werner-Wasik et al.11 reported 
that VRR was an effective prognostic factor of response evaluation in locally-
advanced NSCLC patients. Since then, however, no studies have produced 
meaningful results regarding volume changes in lung cancer. This study was the first 
attempt to reveal the prognostic importance of VRR in SCLC.
The ETVRR ≤45% group patients showed poor OS and LRPFS (8.3 and 6.3 
months, respectively) and this was relatively poor survival outcome than previous 
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studies. The reason was because of early loco-regional failure in ipsilateral lung 
parenchyme (n = 2) and brain metastasis (n = 1).
This study has some limitations. Established prognostic factors in SCLC 
(age, sex, ECOG PS, SER, initial GTV, and overall treatment response) were not 
significantly correlated with survival outcome in this study, which may have been 
influenced by the relatively small number of patients included in analysis. Not all 
patients were subjected to adaptive planning, and ETVRR was determined in only 30 
of 47 patients. Currently, most SCLC patients treated with CRT at our institution 
undergo adaptive planning; a longer follow-up with a larger number of patients will 
reveal the validity of these results.
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V. CONCLUSION
In conclusion, overall and early treatment responses to chemo-radiation in 
LS-SCLC as measured by volume reduction were favorable. Patients who showed an 
early treatment response (ETVRR >45%) had better treatment outcome in terms of 
PFS and OS than those who did not. ETVRR as a parameter for early treatment 
response may be a useful prognostic factor of treatment outcome in LS-SCLC patients 
treated with CRT.
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<ABSTRACT (IN KOREAN)>
항암방사선치료를 받은 제한기 소세포성 폐암 환자에서
예후인자로서의 초기치료 체적감소율
<지도교수 이 창 걸>
연세대학교 대학원 의학과
이 주 환
목적: 근치적 목적의 항암방사선치료를 받은 제한기 소세포성 폐암
환자에서의 초기 치료반응이 향후 치료성적을 예측할 수 있는 예후
인자로서 의미가 있는지를 밝히고자 한다. 
재료 및 방법: 2009년 1월부터 2012년 12월까지 본원에서 근치적
항암방사선치료를 받은 47명의 제한기 소세포성 폐암 환자에 대해서
후향적 분석을 시행하였다. 환자들은 중앙값 54 Gy (범위, 46-64 Gy)
의 흉부 방사선치료 및 동시 항암 치료를 시행 받았으며, 항암치료
는 15명 (31.9%)의 환자에서 etoposide/cisplatin, 32명 (68.1%)의
환자에서 etoposide/carboplatin 요법을 진행하였다. 초기 치료반응
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을 나타내는 지표로서 초기치료 체적감소율 (Early treatment 
volume reduction rate)을 제안하였으며, 이는 진단에 사용된 컴퓨터
단층 촬영 (Computed Tomography. CT)과 방사선 치료 도중 치료
적응을 위해 시행한 설계용 컴퓨터 단층 촬영 간의 육안적 종양 체
적의 백분율 감소 정도로 정의하였다. 치료 적응시의 중앙 방사선치
료 선량은 36 Gy (범위, 30-43 Gy) 였으며, 치료 적응을 위한 컴퓨
터 단층 촬영은 30명 (63.8%)의 환자에서 시행되었다.     
결과: 대상환자의 중앙추적관찰기간은 27.7 개월 (범위, 5.9-75.8 개
월) 이었다. 추적관찰 결과 2년 생존률, 무병 생존률, 국소 무병생존
률, 원격전이 무병생존률은 각각 56.5%, 50.6%, 74.2%, 70.1% 였다. 
진단용 컴퓨터 단층 촬영에서의 평균 육안적 종양 체적은 117.9cc 
(범위, 5.9-447cc) 였고 적응용 CT 상에서의 육안적 종양 체적은
36.8cc (범위, 0.3-230.6cc) 였다. 초기치료 체적감소율의 중앙값은
71.4% (범위, 30-97.6%) 였고 45%를 기준으로 보다 많이 감소한
군에서 2년 생존률 (p <0.0001) 및 국소 무병 생존률 (p = 0.009)에
서 유의한 예후 인자로 확인되었다. 
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결론: 초기치료체적감소율 (ETVRR)은 항암방사선치료를 받은 제한
기 소세포성 폐암 환자에서 치료 결과를 예측하기 위한 유용한 예후
인자로 사용될 수 있다. 
핵심되는 말: 소세포성 폐암, 육안적 종양체적, 초기 치료반응, 체적
감소율
